التفاصيل البيبلوغرافية
| العنوان: |
Precision Medicine for Blood Glutamate Grabbing in Ischemic Stroke. |
| المؤلفون: |
Hervella, Pablo, Sampedro-Viana, Ana, Fernández-Rodicio, Sabela, Rodríguez-Yáñez, Manuel, López-Dequidt, Iria, Pumar, José M., Mosqueira, Antonio J., Bazarra-Barreiros, Marcos, Abengoza-Bello, María Teresa, Ortega-Espina, Sara, Ouro, Alberto, Pérez-Mato, María, Campos, Francisco, Sobrino, Tomás, Castillo, José, Alonso-Alonso, Maria Luz, Iglesias-Rey, Ramón |
| المصدر: |
International Journal of Molecular Sciences; Jun2024, Vol. 25 Issue 12, p6554, 14p |
| مصطلحات موضوعية: |
ISCHEMIC stroke, ASPARTATE aminotransferase, GLUTAMIC acid, INDIVIDUALIZED medicine, TUMOR necrosis factors, PEARSON correlation (Statistics), BLOOD-brain barrier |
| مستخلص: |
Glutamate grabbers, such as glutamate oxaloacetate transaminase (GOT), have been proposed to prevent excitotoxicity secondary to high glutamate levels in stroke patients. However, the efficacy of blood glutamate grabbing by GOT could be dependent on the extent and severity of the disruption of the blood–brain barrier (BBB). Our purpose was to analyze the relationship between GOT and glutamate concentration with the patient's functional status differentially according to BBB serum markers (soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and leukoaraiosis based on neuroimaging). This retrospective observational study includes 906 ischemic stroke patients. We studied the presence of leukoaraiosis and the serum levels of glutamate, GOT, and sTWEAK in blood samples. Functional outcome was assessed using the modified Rankin Scale (mRS) at 3 months. A significant negative correlation between GOT and glutamate levels at admission was shown in those patients with sTWEAK levels > 2900 pg/mL (Pearson's correlation coefficient: −0.249; p < 0.0001). This correlation was also observed in patients with and without leukoaraiosis (Pearson's correlation coefficients: −0.299; p < 0.001 vs. −0.116; p = 0.024). The logistic regression model confirmed the association of higher levels of GOT with lower odds of poor outcome at 3 months when sTWEAK levels were >2900 pg/mL (OR: 0.41; CI 95%: 0.28–0.68; p < 0.0001) or with leukoaraiosis (OR: 0.75; CI 95%: 0.69–0.82; p < 0.0001). GOT levels are associated with glutamate levels and functional outcomes at 3 months, but only in those patients with leukoaraiosis and elevated sTWEAK levels. Consequently, therapies targeting glutamate grabbing might be more effective in patients with BBB dysfunction. [ABSTRACT FROM AUTHOR] |
|
Copyright of International Journal of Molecular Sciences is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder